Health ❯ Healthcare ❯ Pharmacology

Antibody-Drug Conjugates

B7-H3 Targeting Sacituzumab Govitecan

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

SABCS presentations underscore subtype‑specific use requiring careful treatment sequencing.

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2